PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...
PDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 combo
PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in ...
Morningstar3d
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
“MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an ...
manilatimes3d
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
"MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an unmet ...
Technology Networks5d
Overcoming CAR T-Cell Therapy Limitations
In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...
PDS Biotech gets IND application clearance for colorectal cancer treatment
PDS Biotechnology (NASDAQ:PDSB) said on Thursday it received U.S. FDA clearance for its Investigational New Drug application ...
Precision Medicine Online3d
PDS Biotech Cleared to Begin Trial of Immunotherapy Combo in MUC1-Positive Colorectal Cancer
The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.